Zheng-rong Shi
Chongqing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Comparison of Postoperative Adjuvant CTACE vs DEB-TACE Combined with Tislelizumab and Lenvatinib in BCLC Stage B/C Hepatocellular Carcinoma: A Propensity Score-Matched Analysis of Survival Outcomes.
Journal: Academic radiology
Published: October 11, 2025
The therapeutic efficacy of radical resection for hepatocellular carcinoma varies markedly by tumor location: a retrospective real-world study.
Journal: Frontiers in pharmacology
Published: July 28, 2025
Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab: A case report and review of literature.
Journal: World journal of gastrointestinal oncology
Published: June 26, 2024
Relationships Among Serological Indicators and In Vitro High-Throughput Drug Sensitivity Screening Results in Patients with Hepatocellular Carcinoma.
Journal: Combinatorial chemistry & high throughput screening
Published: March 06, 2024
NUP85 alleviates lipid metabolism and inflammation by regulating PI3K/AKT signaling pathway in nonalcoholic fatty liver disease.
Journal: International journal of biological sciences
Published: November 17, 2023
Benefits of Hypothermic Oxygenated Perfusion Versus Static Cold Storage in Liver Transplant: A Comprehensive Systematic Review and Meta-analysis.
Journal: Journal of clinical and experimental hepatology
Published: October 01, 2023
Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma.
Journal: Journal of cancer research and clinical oncology
Published: March 14, 2023
Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation.
Journal: Journal of experimental & clinical cancer research : CR
Published: February 14, 2023
The combination of a prolonged treatment time window and alpha-fetoprotein benefits the tumor response of hepatocellular carcinoma patients as evaluated by the imRECIST: a single-center, retrospective study.
Journal: Journal of gastrointestinal oncology
Published: January 19, 2023
Last Updated: 09/26/2026